Alper Cagri Karci1, Zeynep Canturk2, Ilhan Tarkun2, Berrin Cetinarslan2. 1. Clinic of Endocrinology and Metabolism, Ankara Numune Training and Research Hospital, Ankara, Turkey. alpercagrkarc@yahoo.com. 2. Department of Endocrinology and Metabolism, Kocaeli University Faculty of Medicine, Kocaeli, Turkey.
Abstract
PURPOSE: During follow-up of acromegaly patients, there is a discordance rate of 30% between the measurements of growth hormone and insulin-like growth factor-1 levels. Further tests are required to determine disease activity in patients with discordant results. This study was planned to investigate an association of serum levels of matrix metalloproteinase-2, matrix metalloproteinase-9, and cathepsin B with disease activity in acromegaly patients. METHODS: In this study, 64 acromegaly patients followed in our clinic were divided into two groups according to the 2010 consensus criteria for cure of acromegaly as patients with active disease (n = 24) and patients with controlled disease (n = 40). Serum matrix metalloproteinase-2, matrix metalloproteinase-9, and cathepsin B levels were measured by the enzyme-linked immunosorbent assay method. RESULTS: The mean serum matrix metalloproteinase-2 level was significantly higher in the active acromegaly patients than in the controlled acromegaly patients (150.1 ± 54.5 ng/mL vs. 100.2 ± 44.6 ng/mL; p < 0.0001). There was no significant difference between the active and controlled acromegaly patients regarding serum matrix metalloproteinase-9 and cathepsin B levels (p = 0.205 and p = 0.598, respectively). Serum matrix metalloproteinase-2 levels of 118.3 ng/mL and higher had a sensitivity of 75% and a specificity of 77.5% in determining active disease. The risk of active acromegaly was 3.3 fold higher in the patients with a matrix metalloproteinase-2 level of >118.3 ng/mL than in the patients with a matrix metalloproteinase-2 level of <118.3 ng/mL. CONCLUSIONS: In this study, serum matrix metalloproteinase-2 level is increased in the active acromegaly patients and a threshold value in determining active disease was defined for serum matrix metalloproteinase-2 level. This study is the first to compare acromegaly patients having active or controlled disease in terms of matrix metalloproteinase-2 and matrix metalloproteinase-9 levels. The results need to be confirmed by a study that will be conducted in a larger patient group also including a healthy control group to demonstrate the value of this novel marker in disease activity.
PURPOSE: During follow-up of acromegalypatients, there is a discordance rate of 30% between the measurements of growth hormone and insulin-like growth factor-1 levels. Further tests are required to determine disease activity in patients with discordant results. This study was planned to investigate an association of serum levels of matrix metalloproteinase-2, matrix metalloproteinase-9, and cathepsin B with disease activity in acromegalypatients. METHODS: In this study, 64 acromegalypatients followed in our clinic were divided into two groups according to the 2010 consensus criteria for cure of acromegaly as patients with active disease (n = 24) and patients with controlled disease (n = 40). Serum matrix metalloproteinase-2, matrix metalloproteinase-9, and cathepsin B levels were measured by the enzyme-linked immunosorbent assay method. RESULTS: The mean serum matrix metalloproteinase-2 level was significantly higher in the active acromegalypatients than in the controlled acromegalypatients (150.1 ± 54.5 ng/mL vs. 100.2 ± 44.6 ng/mL; p < 0.0001). There was no significant difference between the active and controlled acromegalypatients regarding serum matrix metalloproteinase-9 and cathepsin B levels (p = 0.205 and p = 0.598, respectively). Serum matrix metalloproteinase-2 levels of 118.3 ng/mL and higher had a sensitivity of 75% and a specificity of 77.5% in determining active disease. The risk of active acromegaly was 3.3 fold higher in the patients with a matrix metalloproteinase-2 level of >118.3 ng/mL than in the patients with a matrix metalloproteinase-2 level of <118.3 ng/mL. CONCLUSIONS: In this study, serum matrix metalloproteinase-2 level is increased in the active acromegalypatients and a threshold value in determining active disease was defined for serum matrix metalloproteinase-2 level. This study is the first to compare acromegalypatients having active or controlled disease in terms of matrix metalloproteinase-2 and matrix metalloproteinase-9 levels. The results need to be confirmed by a study that will be conducted in a larger patient group also including a healthy control group to demonstrate the value of this novel marker in disease activity.
Authors: M Páez Pereda; M F Ledda; V Goldberg; A Chervín; G Carrizo; H Molina; A Müller; U Renner; O Podhajcer; E Arzt; G K Stalla Journal: J Clin Endocrinol Metab Date: 2000-01 Impact factor: 5.958
Authors: S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina Journal: J Clin Endocrinol Metab Date: 2009-02-10 Impact factor: 5.958
Authors: G A Kanakis; A Chrisoulidou; A Bargiota; Z A Efstathiadou; L Papanastasiou; A Theodoropoulou; S K Tigas; D A Vassiliadi; S Tsagarakis; M Alevizaki Journal: Clin Endocrinol (Oxf) Date: 2016-07-14 Impact factor: 3.478
Authors: Ulrich J Knappe; Christian Hagel; Björn W Lisboa; Waldemar Wilczak; Dieter K Lüdecke; Wolfgang Saeger Journal: Acta Neuropathol Date: 2003-08-02 Impact factor: 17.088
Authors: Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier Journal: Rev Endocr Metab Disord Date: 2020-12 Impact factor: 6.514